Extrawell Pharmaceutical Holdings Limited

Greenhouse gas emissions & sustainability report data

📊 Latest report period: 2023🗂️ Report periods on file: 2023, 2020-04-01 to 2021-03-31, 2019, 2017-04 to 2018-03, 2016-04-01 to 2017-03-31

In its 2023 reporting, Extrawell Pharmaceutical Holdings Limited disclosed greenhouse gas emissions of 3.0K tonnes CO2e (2022: 2564 tonnes CO2e). By scope: Scope 1: 1.2K tonnes CO2e (2022: 994 tonnes CO2e); Scope 2: 1.8K tonnes CO2e (2022: 1565 tonnes CO2e); Scope 3: 2 tonnes CO2e (2022: 5 tonnes CO2e). Figures are as stated in the company's own report and may use different boundaries, units or methods (for example market-based vs location-based Scope 2), so compare with care.

💨
GHG Emissions
3.0K tonnes CO2e (2022: 2564 tonnes CO2e)
2023
💧
Water Usage
54.8K tonnes (2022: 50183 tonnes)
2023
♻️
Waste
147 tonnes (2022: 141 tonnes)
2023
⚙️
Energy Use
2.6M KWh (2022: 2184000 KWh)
2023

📊 Emissions by Scope (2023)

ScopeWhat it coversReported value
Scope 1Direct emissions from sources the company owns or controls (fuel combustion, company vehicles, process and fugitive emissions).1.2K tonnes CO2e (2022: 994 tonnes CO2e)
Scope 2Indirect emissions from purchased electricity, steam, heat and cooling.1.8K tonnes CO2e (2022: 1565 tonnes CO2e)
Scope 3Other indirect emissions across the value chain (purchased goods, business travel, use of sold products, etc.).2 tonnes CO2e (2022: 5 tonnes CO2e)

New to scopes? Read Scope 1, 2 and 3 emissions explained and market-based vs location-based Scope 2.

📈 Emissions by Report Period

Report periodHeadline emissions figure reported
20233.0K tonnes CO2e (2022: 2564 tonnes CO2e)
2020-04-01 to 2021-03-312.5K tonnes CO2e (Scope 1 & 2)
20195.1K tCO2e/year
2017-04 to 2018-034.4K tCO2e/year

Each row is the headline figure extracted from a different report; scope coverage and methodology can change between years.

✅ Reported Environmental Achievements

🎯 Climate & Sustainability Targets

🔜 Short-term

  • Maintain and strive for reducing the intensity of total GHG emissions and hazardous and non-hazardous wastes from 2023 to 2025.

🌱 ESG Focus Areas

Environmental ProtectionOccupational Health and SafetySocial ResponsibilityCorporate GovernanceSustainable Development

⚠️ Challenges & Risks +

  • Impacts of lingering COVID-19 pandemic, geopolitical tensions, and inflationary pressures.
  • Government-mandated factory lockdown in Changchun, resulting in lower production outputs and supply chain interruptions.
  • Intensified competition in the pharmaceutical market.
  • Pricing pressure due to centralized drug procurement and national drug reimbursement list adjustments.

📋 Report Information

Reporting Period: 2023
Frameworks: Appendix 27 of the Listing Rules